Syndax Pharmaceuticals (SNDX) Could Be 67% Undervalued Following The Failed IPF Trial

Syndax Pharmaceuticals (SNDX) is in focus after reporting that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis failed the primary efficacy endpoint, and the company has halted development for this use.

The failed IPF trial hit Syndax Pharmaceuticals at a weak point, with the 30-day share price return already down 27.23% and the 90-day share price return falling 38.00%. The 1-year total shareholder return declined 12.97%, while the 3-year total shareholder return remains positive at 10.69%, so near-term momentum looks pressured compared with a still constructive multi-year record.

Broaden your watchlist beyond Syndax Pharmaceuticals by scanning a curated set of 21 high quality undiscovered gems that may not be front-page news yet but already show solid fundamental traits.

Syndax Pharmaceuticals now appears to be a business with real oncology assets but a bruised share price after the IPF setback. The key issue is whether the gap between its pipeline potential and current valuation has become too wide.

Most Popular Narrative: 67% Undervalued

Against a last close of $13.15, the most followed narrative anchors Syndax Pharmaceuticals to a fair value of $39.50, so the pullback after the IPF news sits in the context of a much higher long-term scenario.

Fixed operating expense base, together with expanding product sales and cash flow contributions from both franchises, is positioned to drive significant operating leverage, boosting net margins and accelerating the pathway to profitability. Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide robust long-term growth avenues aligned with surging demand for targeted therapies supporting multi-year earnings momentum.

See why 14 investors see Syndax Pharmaceuticals as 67% undervalued.

Result: Fair Value of $39.50 (UNDERVALUED)

Still, Syndax Pharmaceuticals depends heavily on just two late-stage drugs, and any clinical or regulatory setback for Revuforj or Niktimvo could quickly weaken that valuation story.

Find out about the key risks to this Syndax Pharmaceuticals narrative.

Next Steps

Mixed headlines around Syndax Pharmaceuticals do not need to dictate your stance. Move quickly, review the full picture carefully, and weigh the 2 key rewards in detail via 2 key rewards.

Looking for more investment ideas beyond Syndax Pharmaceuticals?

If you stop at Syndax Pharmaceuticals, you miss a wider field of opportunities that may better match your risk tolerance, income needs, or return goals.

• Target dependable income by scanning 7 dividend fortresses that focus on durable payouts many income investors look for.
• Hunt for quality at a sensible price with the 33 high quality undervalued stocks that already clear fundamental checks.
• Prioritise capital protection by reviewing a 31 resilient stocks with low risk scores that tilts toward resilient balance sheets and steadier risk profiles.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com